Quinolone-resistant infection - Symptoms, Causes, Treatment & Prevention

Overview

Quinolone‑resistant infections are bacterial infections that no longer respond to the class of antibiotics known as quinolones (also called fluoroquinolones). These antibiotics—such as ciprofloxacin, levofloxacin, and moxifloxacin—have been widely used for urinary‑tract infections (UTIs), gastrointestinal infections, respiratory infections, skin and soft‑tissue infections, and more. When bacteria develop mechanisms that neutralize the drug’s effect, the infection becomes “quinolone‑resistant,” meaning standard quinolone therapy will fail and alternative antibiotics or treatment strategies are required.

Who it affects: Resistance can appear in anyone who acquires a susceptible bacterium that has mutated or acquired resistance genes. However, certain groups are at higher risk:

• Elderly patients, especially those in long‑term care facilities.
• People with frequent healthcare exposures (hospitalizations, catheter use, dialysis).
• Individuals who have taken quinolones repeatedly or for prolonged periods.
• Patients with weakened immune systems (e.g., HIV, chemotherapy, transplant recipients).

Prevalence: According to the 2023 CDC Antibiotic Resistance Threats Report, fluoroquinolone‑resistant Escherichia coli caused an estimated 2.6 million infections and 23,000 deaths in the United States alone. Globally, the World Health Organization lists quinolone resistance as a “critical” priority for new drug development, with resistance rates >30 % reported in many low‑ and middle‑income countries for common pathogens such as Salmonella, Shigella, and Staphylococcus aureus.^[1][2]

Symptoms

The clinical picture depends on the organ system involved. Below is a symptom checklist for the most common quinolone‑resistant infections.

Urinary‑tract infection (UTI)

• Burning sensation or pain during urination
• Frequent urge to urinate, often with only small amounts
• Cloudy, dark, or foul‑smelling urine
• Hematuria (blood in urine)
• Lower abdominal or pelvic pain
• Fever, chills, or fatigue (signs of upper‑tract involvement)

Gastrointestinal infection (e.g., Campylobacter, Salmonella)

• Diarrhea (may be watery or bloody)
• Abdominal cramping and pain
• Nausea and vomiting
• Fever of 38 °C (100.4 °F) or higher
• Dehydration (dry mouth, dizziness, reduced urine output)

Respiratory infection (e.g., community‑acquired pneumonia)

• Persistent cough, sometimes producing sputum
• Chest pain that worsens with deep breathing
• Shortness of breath
• Fever, chills, night sweats
• Fatigue, muscle aches

Skin and soft‑tissue infection

• Redness, warmth, swelling at the infection site
• Pain or tenderness
• Pus or other drainage
• Fever or chills (if systemic spread)

Bloodstream infection (bacteremia) or sepsis

• High fever (≥38.5 °C/101.3 °F) or hypothermia
• Rapid heart rate (tachycardia)
• Rapid breathing (tachypnea)
• Confusion, altered mental status
• Low blood pressure (possible shock)

Because quinolone resistance may lead to treatment failure, symptoms often persist or worsen despite appropriate‑appearing therapy. Any lack of improvement after 48–72 hours warrants re‑evaluation.

Causes and Risk Factors

Mechanisms of resistance

• Target‑site mutations: Changes in bacterial DNA gyrase (gyrA) and topoisomerase IV (parC) reduce quinolone binding.
• Efflux pumps: Over‑expression of proteins that expel quinolones from the bacterial cell.
• Plasmid‑mediated genes: Genes such as qnr, aac(6')‑Ib‑cr, and qepA can be transferred between bacteria, spreading resistance quickly.

Primary risk factors

• Recent or repeated quinolone use (≥3 courses in the past 6 months).
• Hospitalization, especially ICU stays or surgical procedures.
• Indwelling devices (urinary catheters, central lines, prosthetic joints).
• Travel to regions with high resistance prevalence (South Asia, parts of Africa, Latin America).
• Exposure to contaminated water or food (e.g., undercooked poultry, unpasteurized dairy).
• Chronic comorbidities: diabetes, chronic kidney disease, COPD.

Diagnosis

Accurate diagnosis requires both clinical suspicion and laboratory confirmation.

Step‑by‑step approach

1. History and physical exam: Identify site of infection, symptom duration, prior antibiotic exposures.
2. Specimen collection: Urine (mid‑stream), sputum, wound swab, blood cultures, or stool—depending on suspected site.
3. Microbiological culture: Grow the organism on appropriate media. Most labs perform susceptibility testing automatically.
4. Antibiotic susceptibility testing (AST):
   • Disk diffusion (Kirby‑Bauer) or broth microdilution to determine minimum inhibitory concentration (MIC).
   • Interpretation follows Clinical & Laboratory Standards Institute (CLSI) breakpoints; an MIC ≥2 µg/mL for ciprofloxacin, for example, indicates resistance.
5. Molecular testing (optional but increasingly common):
   • PCR assays for qnr, aac(6')‑Ib‑cr, and other resistance genes.
   • Whole‑genome sequencing in outbreak investigations.
6. Imaging (if indicated): Ultrasound for pyelonephritis, chest x‑ray/CT for pneumonia, MRI for osteomyelitis.

When a culture grows a quinolone‑susceptible organism but the patient fails to improve on quinolone therapy, clinicians should suspect either an inaccurate susceptibility result or a mixed infection and repeat testing.

Treatment Options

Guiding principles

• Base therapy on susceptibility results, not on the usual quinolone regimen.
• Consider the infection site, patient’s kidney and liver function, and potential drug interactions.
• Use the shortest effective duration to minimize further resistance.

Alternative antimicrobial agents

Infection Site	Preferred Alternative(s)	Key Considerations
UTI (uncomplicated)	Trimethoprim‑sulfamethoxazole (if susceptible), nitrofurantoin, fosfomycin	Avoid in severe renal impairment; check local resistance patterns.
UTI (complicated or pyelonephritis)	Extended‑spectrum β‑lactams (e.g., cefepime, piperacillin‑tazobactam), carbapenems (ertapenem, meropenem) when ESBL risk high	Reserve carbapenems for proven ESBL or multidrug‑resistant organisms.
Gastroenteritis (Campylobacter, Salmonella)	Azithromycin, ertapenem (severe), or ceftriaxone	Azithromycin preferred for outpatient use; monitor for QT prolongation.
Community‑acquired pneumonia	β‑lactam + macrolide (e.g., amoxicillin‑clavulanate + azithromycin) or respiratory fluoroquinolone avoidance; consider doxycycline.	Tailor to local MRSA/MDR prevalence.
Skin & soft‑tissue infection	Clindamycin, doxycycline, linezolid (MRSA coverage), or vancomycin for severe cases	Check for toxin‑mediated disease; clindamycin suppresses toxin production.
Bloodstream infection / sepsis	Broad‑spectrum β‑lactam (cefepime, piperacillin‑tazobactam) ± vancomycin; de‑escalate once susceptibilities known.	Prompt source control (e.g., catheter removal) is critical.

Adjunctive measures

• Source control: Drain abscesses, replace infected catheters, debride necrotic tissue.
• Supportive care: Adequate hydration for GI infections; oxygen for pneumonia; analgesia as needed.
• Antimicrobial stewardship: Review antibiotic choice at 48 hours, switch to narrow‑spectrum agent when possible.

Living with Quinolone‑Resistant Infection

Chronic or recurrent infections can impact daily life. Below are practical strategies to help patients manage their condition.

Medication management

• Keep a written list of all current antibiotics, including dose, timing, and known allergies.
• Use a pill organizer and set alarms to improve adherence.
• Report side‑effects (e.g., rash, gastrointestinal upset) to your provider promptly.

Monitoring & follow‑up

• Schedule a follow‑up visit or phone call within 48–72 hours of starting a new antibiotic to assess response.
• For urinary infections, repeat urine culture if symptoms persist beyond 3 days.
• Track temperature and heart rate at home; maintain a symptom diary.

Lifestyle adjustments

• Stay well‑hydrated (≥2 L water daily) to flush the urinary tract.
• Maintain good hand hygiene—wash hands with soap for at least 20 seconds, especially after using the bathroom.
• Eat a balanced diet rich in fruits, vegetables, and fiber to support gut microbiome health.
• Avoid smoking and limit alcohol, which can impair immune function.

Psychosocial support

• Join patient support groups (online forums, local community groups) to share experiences.
• Consider counseling if chronic infection leads to anxiety or depression.
• Inform caregivers about the infection and the importance of completing prescribed therapy.

Prevention

Preventing quinolone‑resistant infections relies on both personal habits and broader public‑health measures.

Antibiotic stewardship

• Never use antibiotics without a prescription; complete the full course as directed.
• Ask your clinician whether a non‑quinolone agent is appropriate for your condition.
• Encourage your healthcare team to perform culture and susceptibility testing before prescribing.

Infection‑control practices

• Hand hygiene – alcohol‑based hand rubs when soap isn’t available.
• Proper catheter care – keep urinary catheters sealed, change them only when medically indicated.
• Vaccinations – pneumococcal, influenza, and COVID‑19 vaccines reduce secondary bacterial infections.

Environmental & food safety

• Cook poultry, eggs, and meat to safe internal temperatures (≥165 °F / 74 °C).
• Wash fresh produce under running water; avoid raw milk.
• Drink treated or bottled water when traveling to high‑risk regions.

Travel precautions

• Consider prophylactic measures (e.g., hand sanitizer, safe food choices) when visiting countries with documented high rates of quinolone resistance.
• Carry a copy of your medical records, including prior infections and antibiotic allergies.

Complications

If a quinolone‑resistant infection is not effectively treated, complications can be severe and life‑threatening.

• Sepsis and septic shock – leading to multiorgan failure.
• Renal damage – from untreated pyelonephritis or obstructive uropathy.
• Chronic pulmonary disease exacerbation – especially in COPD or asthma patients.
• Osteomyelitis or prosthetic joint infection – requiring prolonged IV antibiotics and possible surgery.
• Recurrent infections – due to colonization with resistant organisms.
• Increased healthcare costs and longer hospital stays – documented average additional cost of $7,500 per quinolone‑resistant infection in US hospitals.^[3]

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2023. https://www.cdc.gov/drugresistance/biggest-threats.html (accessed April 2026).
2. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2023. https://www.who.int/glass (accessed April 2026).
3. Huang SS, et al. Economic burden of antibiotic‑resistant infections in US hospitals. *Health Affairs*. 2022;41(3):354‑363.
4. Mayo Clinic. Urinary tract infection (UTI). https://www.mayoclinic.org/diseases-conditions/ urinary-tract-infection (accessed April 2026).
5. Cleveland Clinic. Antibiotic stewardship: what patients need to know. https://my.clevelandclinic.org/health/articles/antibiotic-stewardship (accessed April 2026).